Can periprosthetic hip joint infections be successfully managed by debridement and prosthesis retention?

Table 3 Overview of 11 studies reporting about prosthesis retention at the site of periprosthetic hip joint infections with regard to the systemic antibiotic therapy

Study	Systemic antibiotic therapy
Aboltins et al[6]	All intravenous glycopeptide or beta-lactam for median 10 (3-29) d
	All oral rifampicin+fusidic acid for median 17 (6-33) mo
Aboltins et al[7]	All intravenous glycopeptide + beta-lactam for median 15 (12-34) d
	All oral rifampicin + fucidic acid or ciprofloxacin for median 356 (230-395) d
Anagnostakos et al[8]	All intravenous for 4 wk + oral for 2 wk
Choi et al[9]	All intravenous for 6 wk
Crockarell et al[10]	41/42 intravenous for 29 (2-72) d
	26/42 oral after iv For 70 (5-376) d; 3/42 chronic suppression
Kelm et al[11]	Intravenous for 2 wk followed by oral for 2 wk
Klouche et al[12]	Intravenous for 6 wk followed by oral for 6 wk
Lee et al[13]	Intravenous for 4-6 wk
Tsukayama et al[2]	Early: intravenous for 4 wk; acute hematogenous: intravenous for 6 wk
Waagsbø et al[3]	Overall duration of antibiotic therapy 0.1 (8.2-14.2) wk, of which intravenous 4.4 (4.2-6.1) wk
Westberg et al[14]	Overall duration of antibiotic therapy 7 (3-39) wk